Quest Diagnostics (NYSE: DGX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Quest Diagnostics reported 37 open-market sales of 201,837 shares ($42.8m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | Delaney Mark E | SVP & Chief Commercial Officer | Grant or award | +2,615 | — | 12,975 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Grant or award, 10b5-1 plan | +4,827 | — | 71,949 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Option exercise, 10b5-1 plan | +22,105 | $121.81 | 94,054 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −3,818 | $245.45 | 90,236 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −5,990 | $246.26 | 84,246 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −1,151 | $246.98 | 83,095 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −2,358 | $248.38 | 80,737 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −3,004 | $249.40 | 77,733 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −2,877 | $250.49 | 74,856 | Form 4 |
| 3 November 2026 | Doherty Catherine T. | Executive Vice President | Open-market sale, 10b5-1 plan | −2,907 | $251.24 | 71,949 | Form 4 |
| 3 November 2026 | Ramachandran Subu | SVP, Regional Businesses | Grant or award | +352 | — | 2,832 | Form 4 |
| 26 October 2026 | Pfeiffer Gary M | Director | Open-market sale, 10b5-1 plan | −1,203 | $243.00 | 29,802 | Form 4 |
| 21 October 2026 | Delaney Mark E | SVP & Chief Commercial Officer | Small acquisition | +25 | $235.94 | 10,360 | Form 4 |
| 21 October 2026 | Main Timothy L | Director | Small acquisition | +18 | $235.94 | 22,478 | Form 4 |
| 21 October 2026 | Plewman Patrick | SVP for Diagnostic Services | Small acquisition | +41 | $235.94 | 15,334 | Form 4 |
| 21 October 2026 | Lassiter Wright III | Director | Small acquisition | +6 | $235.96 | 10,329 | Form 4 |
| 21 October 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | Small acquisition | +33 | $235.94 | 13,619 | Form 4 |
| 21 October 2026 | Gregg Vicky B | Director | Grant or award | +63 | $235.94 | 18,449 | Form 4 |
| 21 October 2026 | Samad Sam | Executive Vice President & CFO | Grant or award | +90 | $235.94 | 33,568 | Form 4 |
| 21 October 2026 | Carter Robert B | Director | Small acquisition | +10 | $235.93 | 3,874 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Quest Diagnostics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.